COMPLETED RESEARCH: CLINICAL TRANSLATIONAL RESEARCH
Abstract #CT09

Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis

Presenter: Senxi Du, Student, Keck School of Medicine of University of Southern California

Co-Authors: Theresa Amoloja, Incyte Corporation, Wilmington, DE; Eileen Peng, Regional Cancer Care Associates, East Brunswick, NJ; Marisa Keck, Regional Cancer Care Associates, East Brunswick, NJ; Ellen Ronnen, Regional Cancer Care Associates, East Brunswick, NJ

Background: Myelofibrosis is a heterogeneous myeloproliferative neoplasm in which risk categorization informs prognosis and treatment.1 Ruxolitinib is indicated for the treatment of patients with intermediate- or high-risk myelofibrosis; starting doses are determined by baseline platelet counts,2 including: 20 mg twice daily for >200 × 109/L; 15 mg twice daily for 100-200 × 109/L; and 5 mg twice daily for 50-<100 × 109/L (dose for <50 × 109/L not established).3,4

Objective: To describe the clinical characteristics and real-world dosing patterns of ruxolitinib among patients with myelofibrosis at a community practice.

Methods: This was a retrospective chart review of adults with confirmed intermediate- or high-risk myelofibrosis who received ruxolitinib between January 1, 2015, and June 20, 2019, at a single community hematology/oncology practice, excluding patients who participated in any myelofibrosis-related clinical trial.

Results: Data from 12 eligible patients were included. The median age was 69 years (range, 56-85 years) at myelofibrosis diagnosis (male, 67%; primary myelofibrosis, 50%). According to the Dynamic International Prognostic Scoring System, at diagnosis, 3 patients had high-risk myelofibrosis, 4 intermediate-2 risk, and 5 intermediate-1 risk; 8 patients had JAK2 mutation, 2 patients had no JAK2 mutation, and 2 patients had other unspecified mutations. At ruxolitinib initiation, the platelet counts were >200 × 109/L (N = 8), 100-200 × 109/L (N = 1), and 50 × 109/L (N = 3). Starting doses varied: 20 mg twice daily (N = 3), 20 mg once daily (N = 1), 15 mg twice daily (N = 2), 10 mg twice daily (N = 2), 5 mg twice daily (N = 3), and 5 mg once daily (N = 1). In all, 7 patients continued ruxolitinib therapy through the study period, with a median duration of 37 months; 4 patients continued the same ruxolitinib dose from initiation until the last visit (5 mg twice daily, N = 2; 20 mg twice daily, N = 1) or ruxolitinib discontinuation (20 mg once daily, N = 1); 3 patients had dose increases, and 5 had decreases. The median time to first dose increase was 0.5 months, and to first dose decrease was 3.5 months. Two patients had dose interruptions (at 3 months and 38 months), and both patients reinitiated ruxolitinib therapy within 1 month. Five patients discontinued ruxolitinib after a median of 8 months for the following reasons: adverse event (initiated at 5 mg twice daily despite having platelets <50 × 109/L), undergoing transplant, patient preference, severe chronic anemia after several dose adjustments, and lack of efficacy (initiated at 20 mg once daily instead of the recommended twice daily).

Conclusion: In a small number of patients with myelofibrosis who were managed at a community practice, a variety of ruxolitinib doses were given, including doses not validated by clinical trials (eg, once-daily doses5,6).

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myeloproliferative Neoplasms. Version 1.2020. May 21, 2020. www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed September 2020.
  2. Jakafi (ruxolitinib) tablets, for oral use [prescribing information]. Incyte Corporation; 2020.
  3. Devos T, Selleslag D, Zachée P, Benghiat FS. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology. 2018;23:194-200.
  4. Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leuk Lymphoma. 2014;55:5-6.
  5. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. . 2010;363:1117-1127.
  6. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81.
Related Items
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.